Regeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales UpZacks Investment Research • 08/01/25
Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challengesWSJ • 08/01/25
Regeneron (REGN) Q2 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 08/01/25
Regeneron Pharmaceuticals Likely To Report Lower Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings CallBenzinga • 08/01/25
Unlocking Q2 Potential of Regeneron (REGN): Exploring Wall Street Estimates for Key MetricsZacks Investment Research • 07/29/25
Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative InnovationGlobeNewsWire • 07/24/25
Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025GlobeNewsWire • 06/26/25
Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance OrganizationGlobeNewsWire • 06/24/25
Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous PemphigoidZacks Investment Research • 06/20/25